Role of Innovator Product Characterization in Generic Product Development
暂无分享,去创建一个
Arvind K. Bansal | Vishal Koradia | Sai H.S. Boddu | Bhushan Munjal | A. Bansal | V. Koradia | S. H. Boddu | Bhushan Munjal
[1] Stephen R Byrn,et al. Solid-state analysis of the active pharmaceutical ingredient in drug products. , 2003, Drug discovery today.
[2] Weiyong. Li,et al. Quantitation of active pharmaceutical ingredients and excipients in powder blends using designed multivariate calibration models by near-infrared spectroscopy. , 2005, International journal of pharmaceutics.
[3] G. Brinkmalm,et al. Development of a size exclusion chromatography method for the determination of molar mass for poloxamers. , 2003, Journal of pharmaceutical and biomedical analysis.
[4] M. J. Thompson,et al. Quantitation of poloxamers in pharmaceutical formulations using size exclusion chromatography and colorimetric methods. , 2004, Journal of pharmaceutical and biomedical analysis.
[5] Robert A. Lionberger,et al. FDA Critical Path Initiatives: Opportunities for Generic Drug Development , 2008, The AAPS Journal.
[6] Determination of ascorbic acid in pharmaceutical preparations by near infrared reflectance spectroscopy. , 1993, Talanta.
[7] A. Hussain,et al. A Modern View of Excipient Effects on Bioequivalence: Case Study of Sorbitol , 2006, Pharmaceutical Research.
[8] Bo Chen,et al. Determination of neotame in beverages, cakes and preserved fruits by column-switching high-performance liquid chromatography , 2010, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.
[9] J. Irache,et al. An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles. , 2007, Journal of pharmaceutical and biomedical analysis.
[10] Christopher A. Mattson,et al. A Generic Formulaic Characterization of the Time to Reverse Engineer the Tolerances of a Product , 2009 .
[11] J. Coello,et al. Quantitation of the active compound and major excipients in a pharmaceutical formulation by near infrared diffuse reflectance spectroscopy with fibre optical probe , 1996 .
[12] Lawrence X. Yu,et al. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). , 2004, Advanced drug delivery reviews.
[13] D. Barends,et al. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] D M Barends,et al. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. , 2005, Journal of pharmaceutical sciences.
[15] Vinod P. Shah,et al. Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.
[16] Stephen Byrn,et al. Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations , 1995, Pharmaceutical Research.
[17] Christos Reppas,et al. Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.
[18] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[19] K. Khanvilkar,et al. Effects of Manufacturing Process Variables on In Vitro Dissolution Characteristics of Extended-Release Tablets Formulated with Hydroxypropyl Methylcellulose , 2003, Drug development and industrial pharmacy.
[20] L. Lesko,et al. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. , 1998, Pharmaceutical development and technology.
[21] David E. Bugay,et al. Physical Characterization of Pharmaceutical Solids , 1995, Pharmaceutical Research.
[22] Arvind K. Bansal,et al. The role of reverse engineering in the development of generic formulations , 2005 .
[23] D. Crommelin,et al. 1H NMR Quantification of poly(Ethylene Glycol)-Phosphatidylethanolamine in Phospholipid Mixtures , 1999, Pharmaceutical Research.
[24] R. Strickley,et al. Drug-Excipient Incompatibility Studies of the Dipeptide Angiotensin-Converting Enzyme Inhibitor, Moexipril Hydrochloride: Dry Powder vs Wet Granulation , 1990, Pharmaceutical Research.
[25] Shiew-Mei Huang,et al. Bioavailability and Bioequivalence: An FDA Regulatory Overview , 2001, Pharmaceutical Research.
[26] H. Kristensen,et al. Quantitative analysis of povidone (PVP) in drug-PVP matrix using multicomponent analysis. , 1999, Drug development and industrial pharmacy.
[27] M. Gj. Overview of the Hatch-Waxman Act and its impact on the drug development process. , 1999 .
[28] P. Desbène,et al. Quantitative trace analysis of surfactant mixtures by reversed-phase high-performance liquid chromatography with refractometric detection , 1996 .
[29] Mario Aranda,et al. Routine Method for Quantification of Starch by Planar Chromatography (HPTLC) , 2005, JPC – Journal of Planar Chromatography – Modern TLC.
[30] C. Vogt,et al. Separation of nonionic surfactants by capillary electrophoresis and high-performance liquid chromatography. , 1998, Analytical chemistry.
[31] P. York. Solid-state properties of powders in the formulation and processing of solid dosage forms , 1983 .
[32] Arvind K. Bansal,et al. Comprehensive Characterisation of the Innovator Product: Targeting Bioequivalent Generics , 2005 .